View in EDS

Factors associated with efficacy of occipital nerve stimulation in medically intractable chronic cluster headache.

Saved in:
Bibliographic Details
Title: Factors associated with efficacy of occipital nerve stimulation in medically intractable chronic cluster headache.
Authors: Brandt, Roemer B. (AUTHOR), Lansbergen, Casper S. (AUTHOR), Kollenburg, Linda (AUTHOR), Ferrari, Michel D. (AUTHOR), Huygen, Frank J. P. M. (AUTHOR), de Vos, Cecile C. (AUTHOR), Fronczek, Rolf (AUTHOR), Ferrari, M. D. (AUTHOR), Wilbrink, L. A. (AUTHOR), de Coo, I. F. (AUTHOR), Doesborg, P.G.G. (AUTHOR), Bartels, E.C. (AUTHOR), van Zwet, E.W. (AUTHOR), Huygen, F.J.P.M. (AUTHOR), Mulleners, W. (AUTHOR), Kurt, E. (AUTHOR), van Dongen, R.T.M. (AUTHOR), Teernstra, O.P. (AUTHOR), Koehler, P.J.J. (AUTHOR), Spincemaille, G.H. (AUTHOR)
Source: Headache: The Journal of Head & Face Pain. Oct2025, Vol. 65 Issue 9, p1626-1633. 8p.
Subjects: Treatment of cluster headaches, Cranial nerve physiology, Chronic disease treatment, Age of onset, Disease duration, Autonomic nervous system, Smoking, Sex distribution, Questionnaires, Logistic regression analysis, Treatment effectiveness, Retrospective studies, Descriptive statistics, Multivariate analysis, Longitudinal method, Odds ratio, Electric stimulation, Medical records, Acquisition of data, Quality of life, Treatment failure, Patient satisfaction, Confidence intervals, Health outcome assessment, Data analysis software, Regression analysis, Neurotransmitters
Geographic Terms: Netherlands
Abstract: Background/Objective: Occipital nerve stimulation (ONS) has become an established therapy for medically intractable chronic cluster headache (MICCH), but unfortunately, one third of the patients do not respond satisfactorily. Reliable predictors of treatment success would help physicians improve indication for ONS in MICCH. Although a recent report suggested several factors that were associated with treatment failure (early onset of cluster headache [CH], chronic cluster headache [CCH], and smoking) this study was small, did not use a formal model, efficacy was poorly defined, and the follow‐up was only of short duration. Here, we retrospectively sought: (i) reproduction of these associations and (ii) identification of possible other associations in our previously published double‐blind randomized controlled "Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache" (ICON) trial, and long‐term follow‐up, of the efficacy of ONS in MICCH. Methods: Data from the double‐blind randomized controlled ICON trial, and its prospective open‐label extension, were analyzed in this prospective cohort study in the Netherlands (October 12, 2010, to December 20, 2020) for: (i) relative differences in attack frequency and (ii) subjective satisfaction with effect between baseline and at 4 and 24 weeks, and 2 and 5 years, after ONS implantation. Formal statistical models were used to: (i) verify the previously detected associations and (ii) identify possible other associations. Results: Early onset of CH and smoking did not predict efficacy of ONS. Relative reduction in attack frequency at 24 weeks (B = 0.44, 95% confidence interval [CI] 0.13–0.76; p = 0.007) and the time since onset of CCH (B = 4.04, 95% CI 1.16–6.92; p = 0.007) appeared to be the only factors that were associated with objective efficacy at 2 years, and relative attack reduction after 2 years was the only factor associated with objective efficacy at 5 years (B = 0.501, 95% CI 0.186–0.815; p = 0.003). The odds of experiencing subjective satisfaction with ONS after 2 years increased with a later debut of CCH (adjusted odds ratio [aOR] 1.06, 95% CI 1.01–1.12; p = 0.033) and greater relative reduction in attack frequency at 24 weeks (aOR 1.02, 95% CI 1.00–1.04; p = 0.017). Conclusion: In a controlled setting, early onset of CH, CCH, and smoking were not associated with treatment success of ONS for MICCH, as previously suggested by others in an uncontrolled setting. Early response at 24 weeks after initiation of ONS was the only factor that was associated with long‐term efficacy, which was identified. Since a large proportion of patients with MICCH improve with ONS, we recommend offering ONS to all patients with MICCH. Plain Language Summary: Previous research has not identified any reliable predictors of treatment response related to the use of occipital nerve stimulation (ONS), but early onset of (chronic) cluster headache and smoking may be associated with treatment failure. We investigated data from a randomized controlled trial and its long‐term follow‐up of occipital nerve stimulation (the ICON trial), and did not find any association between these suggested predictors and treatment response. Our results only showed an association between a positive treatment response at 24 weeks and a positive long‐term treatment response, and since a large proportion of patients with medically intractable chronic cluster headache (MICCH) improve with ONS, we recommend offering ONS to all patients with MICCH. [ABSTRACT FROM AUTHOR]
Copyright of Headache: The Journal of Head & Face Pain is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background/Objective: Occipital nerve stimulation (ONS) has become an established therapy for medically intractable chronic cluster headache (MICCH), but unfortunately, one third of the patients do not respond satisfactorily. Reliable predictors of treatment success would help physicians improve indication for ONS in MICCH. Although a recent report suggested several factors that were associated with treatment failure (early onset of cluster headache [CH], chronic cluster headache [CCH], and smoking) this study was small, did not use a formal model, efficacy was poorly defined, and the follow‐up was only of short duration. Here, we retrospectively sought: (i) reproduction of these associations and (ii) identification of possible other associations in our previously published double‐blind randomized controlled "Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache" (ICON) trial, and long‐term follow‐up, of the efficacy of ONS in MICCH. Methods: Data from the double‐blind randomized controlled ICON trial, and its prospective open‐label extension, were analyzed in this prospective cohort study in the Netherlands (October 12, 2010, to December 20, 2020) for: (i) relative differences in attack frequency and (ii) subjective satisfaction with effect between baseline and at 4 and 24 weeks, and 2 and 5 years, after ONS implantation. Formal statistical models were used to: (i) verify the previously detected associations and (ii) identify possible other associations. Results: Early onset of CH and smoking did not predict efficacy of ONS. Relative reduction in attack frequency at 24 weeks (B = 0.44, 95% confidence interval [CI] 0.13–0.76; p = 0.007) and the time since onset of CCH (B = 4.04, 95% CI 1.16–6.92; p = 0.007) appeared to be the only factors that were associated with objective efficacy at 2 years, and relative attack reduction after 2 years was the only factor associated with objective efficacy at 5 years (B = 0.501, 95% CI 0.186–0.815; p = 0.003). The odds of experiencing subjective satisfaction with ONS after 2 years increased with a later debut of CCH (adjusted odds ratio [aOR] 1.06, 95% CI 1.01–1.12; p = 0.033) and greater relative reduction in attack frequency at 24 weeks (aOR 1.02, 95% CI 1.00–1.04; p = 0.017). Conclusion: In a controlled setting, early onset of CH, CCH, and smoking were not associated with treatment success of ONS for MICCH, as previously suggested by others in an uncontrolled setting. Early response at 24 weeks after initiation of ONS was the only factor that was associated with long‐term efficacy, which was identified. Since a large proportion of patients with MICCH improve with ONS, we recommend offering ONS to all patients with MICCH. Plain Language Summary: Previous research has not identified any reliable predictors of treatment response related to the use of occipital nerve stimulation (ONS), but early onset of (chronic) cluster headache and smoking may be associated with treatment failure. We investigated data from a randomized controlled trial and its long‐term follow‐up of occipital nerve stimulation (the ICON trial), and did not find any association between these suggested predictors and treatment response. Our results only showed an association between a positive treatment response at 24 weeks and a positive long‐term treatment response, and since a large proportion of patients with medically intractable chronic cluster headache (MICCH) improve with ONS, we recommend offering ONS to all patients with MICCH. [ABSTRACT FROM AUTHOR]
ISSN:00178748
DOI:10.1111/head.14985